Restoration of oral all-trans retinoic acid bioavailability after a brief drug holiday

American Journal of Therapeutics

Volumn 4, Issue 4, 1997, Pages 134-140

  Atiba, Joshua O ^a   Manzardo, Ann M ^a   Thiruvengadam, Raghu ^a   Schell, Michael J ^a   Meyskens Jr , Frank L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Bioavailability; Lung carcinoma; Pharmacokinetics

Indexed keywords

CISPLATIN; ETOPOSIDE; RETINOIC ACID;

ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030986729     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199704000-00005     Document Type: Article

References (16)

1. Huang M-E, Ye Y-C, Chen S-R, et al.: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567.
2. Castaigne S, Chomienne C, Daniel MT, et al.: All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia: I. Clinical results. Blood 1990;76: 1704.
3. Warrell RP Jr, Frankel SR, Miller WH Jr, et al.: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). N Engl J Med 1991;324: 1585.
4. Muindi JRF, Frankel SR, Huselton C, et al.: Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res 1992;52:2138-2142.
5. Muindi J, Frankel SR, Miller WH Jr, et al.: Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. Blood 1992;79:299-303.
6. 1. Proc Am Assoc Cancer Res 1994;35:243.
7. Kraft JC, Slikker W Jr, Bailey JR, et al.: Plasma pharmacokinetics and metabolism of 13-cis and all-trans retinoic acid in the cynomolgus monkey and the identification of 13-cis and all-trans retinoyl-beta-glucuranides. A comparison to one human case study with isotrentinoin. Drug Metab Dispo 1991;19:317-324.
8. Rigas JR, Francis PA, Muindi JRF, et al.: Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans retinoic acid, and its modulation by ketoconazole. J Nat Cancer Inst 1993;85:1921-1926.
9. Miller VA, Rigas JR, Tong WP, Kris MG, Warrel RP Jr: Modulation of all-trans retinoic acid pharmacokinetics by liarozole. Proc Am Assoc Cancer Res 1994;35:422.
10. Boylan JF, Gudas LJ: Overexpression of the cellular retinoic acid binding protein-I (CRABP-I) results in a reduction in differentiation-specific gene expression in F9 teratocarcinoma cells. J Cell Biol 1991;112:965-979.
11. Stoner CM, Gudas LJ: Mouse cellular retinoic acid binding protein: cloning, complementary DNA sequence, and messenger RNA expression during the retinoic acid-induced differentiation of F9 wild type and RA-3-10 mutant teratocarcinoma cells. Cancer Res 1989;49:1497-1504.
12. Boylan JF, Gudas LJ: The level of CRABP-I expression influences the amounts and types of all-trans-retinoic acid metabolites in F9 teratocarcinoma stem cells. J Biol Chem 1992;267:21486-21491.
13. Blaner WS, Shuanghong W, Kurlandsky SB, et al.: Retinoid transport in rodents. In: Retinoids from Basic Science to Clinical Applications. (Eds. Tivrea MA, Vidali G), Basel: Birkhauser Verlag, 1994, pp. 53-78.
14. Adamson PC, Balis FM, Smith MA, Murphy RF, Godwin KA, Poplack DG: Dose-dependent pharmacokinetics of all-trans-retinoic acid. J Nat Cancer Inst 1992;84:17
15. Adamson PC, Boylan JF, Balis FM: Time course of induction of metabolism of all-trans-retinoic acid and the up-regulation of cellular retinoic acid-binding protein. Cancer Res 1993;53:472-476.
16. Bugge CJL, Rodriguez LC, Vane FM: Determination of isotretinoin or etretinate and their major metabolites in human blood by reverse-phase high-performance liquid chromatography. J Pharm Biomed Anal 1985;3:260-277.